E-LIB Suche - Ergebnisse für: Knoebl, P.

1

OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with C..:

Coppo, P. ; Patwari, P. ; Mellgård, B....
Research and Practice in Thrombosis and Haemostasis. 7 (2023) - p. 100534 , 2023

Link: https://doi.org/10.1016/..

2

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HE..:

Hampton, K ; Knoebl, P ; Odgaard-Jensen, J...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S458-S459 , 2023

Link: https://doi.org/10.1016/..

3

OC 14.5 Plasma Exchange-free Management of Immune Thromboti..:

Kühne, L. ; Knoebl, P. ; Eller, K....
Research and Practice in Thrombosis and Haemostasis. 7 (2023) - p. 100532 , 2023

Link: https://doi.org/10.1016/..

4

PB0313 Towards the Standardisation of ADAMTS-13 Antibody Te..:

Baker, R. ; Tiao, J. ; Gilmore, G....
Research and Practice in Thrombosis and Haemostasis. 7 (2023) - p. 101473 , 2023

Link: https://doi.org/10.1016/..

5

LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive..:

Tiede, A. ; Hart, C. ; Knoebl, P....
Research and Practice in Thrombosis and Haemostasis. 7 (2023) - p. 100289 , 2023

Link: https://doi.org/10.1016/..

6

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ..:

Knoebl, P. ; de Haard, H. ; Parys, W....
HemaSphere. 6 (2022) - p. 2175-2176 , 2022

Link: https://doi.org/10.1097/..

7

Caplacizumab induces fast and durable platelet count respon..:

Kaynar, L. ; Coppo, P. ; Scully, M....
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 62-63 , 2020

Link: https://doi.org/10.1016/..

8

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THR..:

Scully, M. ; Rubia, J.L. ; Peyvandi, F....
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 95 , 2020

Link: https://doi.org/10.1016/..

9

Safety of caplacizumab in patients without documented sever..:

Besisik, S. ; Rubia, J. De La ; Peyvandi, F....
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 62 , 2020

Link: https://doi.org/10.1016/..

10

Résultats d'efficacité d'une analyse intégrée des essais cl..:

Coppo, P. ; Scully, M. ; Cataland, S....
La Revue de Médecine Interne. 40 (2019) - p. A76-A77 , 2019

Link: https://doi.org/10.1016/..

11

Résultats de l'essai de phase III HERCULES – Essai contrôlé..:

Scully, M. ; Cataland, S. ; Peyvandi, F....
La Revue de Médecine Interne. 39 (2018) - p. A61-A62 , 2018

Link: https://doi.org/10.1016/..

12

A randomized trial of safety, pharmacokinetics and pharmaco..:

Eichler, H. ; Angchaisuksiri, P. ; Kavakli, K....
Journal of Thrombosis and Haemostasis. 16 (2018) 11 - p. 2184-2195 , 2018

Link: https://doi.org/10.1111/..

13

Safety and pharmacokinetics of anti‐TFPI antibody (concizum..:

Chowdary, P. ; Lethagen, S. ; Friedrich, U....
Journal of Thrombosis and Haemostasis. 13 (2015) 5 - p. 743-754 , 2015

Link: https://doi.org/10.1111/..

14

Inhibition of tissue factor pathway inhibitor by the aptame..:

GORCZYCA, M. E. ; NAIR, S. C. ; JILMA, B....
Journal of Thrombosis and Haemostasis. 10 (2012) 8 - p. 1581-1590 , 2012

Link: https://doi.org/10.1111/..

15

Demographic and clinical data in acquired hemophilia A: res..:

KNOEBL, P. ; MARCO, P. ; BAUDO, F....
Journal of Thrombosis and Haemostasis. 10 (2012) 4 - p. 622-631 , 2012

Link: https://doi.org/10.1111/..